vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

Core Insights - vTv Therapeutics is advancing its cadisegliatin program, which is being evaluated as a potential first-in-class oral adjunct therapy for type 1 diabetes (T1D) [2][3] - The company has reinitiated screening in its Phase 3 CATT1 trial and expects topline data in the second half of 2026 following a protocol amendment that shortens the trial duration from 12 to 6 months [3][6] Company Developments - Financial results for Q1 2025 show a net loss of $5.1 million, or $0.77 per share, compared to a net loss of $4.9 million, or $1.17 per share, in Q1 2024 [6][9] - The cash position as of March 31, 2025, was $31.1 million, down from $36.7 million as of December 31, 2024 [6][7] - Research and Development (R&D) expenses increased to $2.8 million in Q1 2025 from $2.6 million in Q1 2024, reflecting higher indirect costs [6][9] - General and Administrative (G&A) expenses decreased to $3.7 million in Q1 2025 from $4.0 million in Q1 2024, primarily due to lower payroll and legal expenses [6][9] Financial Overview - Total operating expenses for Q1 2025 were $6.5 million, slightly down from $6.6 million in Q1 2024 [9] - The company reported no revenue for Q1 2025, compared to $1 million in Q1 2024 [9] - Total assets as of March 31, 2025, were $32.0 million, down from $38.3 million as of December 31, 2024 [7][8] Product Information - Cadisegliatin (TTP399) is a novel oral small molecule being investigated for its potential to improve glycemic control in T1D patients by selectively activating glucokinase in the liver [10][12]